FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis

Zhu,Feng; Niu,Rong; Shao,Xiaoliang; Shao,Xiaonan

doi:10.3892/ijmm.2020.4816

FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis

Authors:
- Feng Zhu
- Rong Niu
- Xiaoliang Shao
- Xiaonan Shao
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, Wuxi Fifth People's Hospital, Wuxi, Jiangsu 214000, P.R. China, Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China
Published online on: December 14, 2020 https://doi.org/10.3892/ijmm.2020.4816
Pages: 523-532
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported that long non‑coding (lnc) RNA FGD5‑antisense 1 (FGD5‑AS1) promotes tumor proliferation, migration and invasion. Therefore, the present study aimed to elucidate the biological role and underlying molecular mechanisms of FGD5‑AS1 in cisplatin (DDP) resistance of lung adenocarcinoma (LAD) cells. The results demonstrated that FGD5‑AS1 was highly expressed in DDP‑resistant LAD tissues and cells. Knockdown of FGD5‑AS1 decreased the proliferative, migratory and invasive abilities of DDP‑resistant LAD cells. Moreover, it was identified that FGD5‑AS1 acted as a molecular sponge for microRNA (miR)‑142, and FGD5‑AS1 enhanced the resistance of A549/DDP cells to DDP by directly interacting with miR‑142. Programmed cell death 1 ligand 1 (PD‑L1) was also found to be a key effector of the FGD5‑AS1/miR‑142 axis to regulate the chemoresistance of DDP‑resistant LAD cells. In conclusion, the present study demonstrated that FGD5‑AS1 increased DDP resistance of LAD via the miR‑142/PD‑L1 axis, which may offer a novel treatment strategy for patients with DDP‑resistant LAD.

View Figures

View References

1	Tang H, Han X, Li M, Li T and Hao Y: Linc00221 modulates cisplatin resistance in non-small-cell lung cancer via sponging miR-519a. Biochimie. 162:134–143. 2019. View Article : Google Scholar : PubMed/NCBI
2	Huang T, Li J, Zhang C, Hong Q, Jiang D, Ye M and Duan S: Distinguishing lung adenocarcinoma from lung squamous cell carcinoma by two hypomethylated and three hypermethylated genes: A meta-analysis. PLoS One. 11:e01490882016. View Article : Google Scholar : PubMed/NCBI
3	Xu R, Mao Y, Chen K, He W, Shi W and Han Y: The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells. Oncotarget. 8:39177–39184. 2017. View Article : Google Scholar : PubMed/NCBI
4	Yang M, He X, Huang X, Wang J, He Y and Wei L: LncRNA MIR4435-2HG-mediated upregulation of TGF-β1 promotes migration and proliferation of nonsmall cell lung cancer cells. Environ Toxicol. 35:582–590. 2020. View Article : Google Scholar
5	Zhao M, Xin XF, Zhang JY, Dai W, Lv TF and Song Y: LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling. Cancer Med. 9:1196–1208. 2020. View Article : Google Scholar
6	Hu M, Zhang Q, Tian XH, Wang JL, Niu YX and Li G: lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis. Mol Carcinog. 58:2207–2217. 2019. View Article : Google Scholar : PubMed/NCBI
7	Yan P, Su Z, Zhang Z and Gao T: LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR-9-5p and regulating SPAG9 expression. Int J Oncol. 55:988–1002. 2019.PubMed/NCBI
8	Chen Z, Ju H, Zhao T, Yu S, Li P, Jia J, Li N, Jing X, Tan B and Li Y: hsa_circ_0092306 targeting miR-197-3p promotes gastric cancer development by regulating PRKCB in MKN-45 cells. Mol Ther Nucleic Acids. 18:617–626. 2019. View Article : Google Scholar : PubMed/NCBI
9	Chen H, Lan Z, Li Q and Li Y: Abnormal expression of long noncoding RNA FGD5-AS1 affects the development of periodontitis through regulating miR-142-3p/SOCS6/NF-κB pathway. Artif Cells Nanomed Biotechnol. 47:2098–2106. 2019. View Article : Google Scholar : PubMed/NCBI
10	Zhu H, Lu J, Zhao H, Chen Z, Cui Q, Lin Z, Wang X, Wang J, Dong H, Wang S and Tan J: Functional long noncoding RNAs (lncRNAs) in clear cell kidney carcinoma revealed by reconstruction and comprehensive analysis of the lncRNA-miRNA-mRNA regulatory network. Med Sci Monit. 24:8250–8263. 2018. View Article : Google Scholar : PubMed/NCBI
11	Sun L, Liu X, Pan B, Hu X, Zhu Y, Su Y, Guo Z, Zhang G, Xu M, Xu X, et al: Serum exosomal miR-122 as a potential diagnostic and prognostic biomarker of colorectal cancer with liver metastasis. J Cancer. 11:630–637. 2020. View Article : Google Scholar : PubMed/NCBI
12	Qin Y, Zhou X, Huang C, Li L, Liu H, Liang N, Chen Y, Ma D, Han Z, Xu X, et al: Serum miR-342-3p is a novel diagnostic and prognostic biomarker for non-small cell lung cancer. Int J Clin Exp Pathol. 11:2742–2748. 2018.PubMed/NCBI
13	Liang ZX, Liu HS, Wang FW, Xiong L, Zhou C, Hu T, He XW, Wu XJ, Xie D, Wu XR and Lan P: LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization. Cell Death Dis. 10:8292019. View Article : Google Scholar : PubMed/NCBI
14	Fan LY, Shi KY, Xu D, Ren LP, Yang P, Zhang L, Wang F and Shao GL: LncRNA GIHCG regulates microRNA-1281 and promotes malignant progression of breast cancer. Eur Rev Med Pharmacol Sci. 23:10842–10850. 2019.PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Yang QS, Li B, Xu G, Yang SQ, Wang P, Tang HH and Liu YY: Long noncoding RNA LINC00483/microRNA-144 regulates radiosensitivity and epithelial-mesenchymal transition in lung adenocarcinoma by interacting with HOXA10. J Cell Physiol. 234:11805–11821. 2019. View Article : Google Scholar : PubMed/NCBI
17	Xiao J, Lv Y, Jin F, Liu Y, Ma Y, Xiong Y, Liu L, Zhang S, Sun Y, Tipoe GL, et al: LncRNA HANR promotes tumorigenesis and increase of chemoresistance in hepatocellular carcinoma. Cell Physiol Biochem. 43:1926–1938. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhang J, Xu C, Gao Y, Wang Y, Ding Z, Zhang Y, Shen W, Zheng Y and Wan Y: A novel long non-coding RNA, MSTRG.51053.2 regulates cisplatin resistance by sponging the miR-432-5p in non-small cell lung cancer cells. Front Oncol. 10:2152020. View Article : Google Scholar : PubMed/NCBI
19	Zheng F and Xu R: CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis. Biomed Pharmacother. 124:1098282020. View Article : Google Scholar : PubMed/NCBI
20	Wang DY, Li N and Cui YL: Long non-coding RNA CCAT1 sponges miR-454 to promote chemoresistance of ovarian cancer cells to cisplatin by regulation of surviving. Cancer Res Treat. 52:798–814. 2020. View Article : Google Scholar : PubMed/NCBI
21	Qu W, Huang W, Yang F, Ju H and Zhu G: Long noncoding RNA LINC00461 mediates cisplatin resistance of rectal cancer via miR-593-5p/CCND1 axis. Biomed Pharmacother. 124:1097402020. View Article : Google Scholar : PubMed/NCBI
22	Wu L, Liu C and Zhang Z: Knockdown of lncRNA MIAT inhibits proliferation and cisplatin resistance in non-small cell lung cancer cells by increasing miR-184 expression. Oncol Lett. 19:533–541. 2020.PubMed/NCBI
23	Dai D, Feng XD, Zhu WQ and Bao YN: LncRNA BLACAT1 regulates the viability, migration and invasion of oral squamous cell carcinoma cells by targeting miR-142-5p. Eur Rev Med Pharmacol Sci. 23:10313–10323. 2019.PubMed/NCBI
24	Li M, Cai O and Tan S: LOXL1-AS1 drives the progression of gastric cancer via regulating miR-142-5p/PIK3CA axis. Onco Targets Ther. 12:11345–11357. 2019. View Article : Google Scholar
25	Liu H, Chen R, Kang F, Lai H and Wang Y: KCNQ1OT1 promotes ovarian cancer progression via modulating MIR-142-5p/CAPN10 axis. Mol Genet Genomic Med. 8:e10772020.PubMed/NCBI
26	Li X, Chen W, Jin Y, Xue R, Su J, Mu Z, Li J and Jiang S: miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol. 161:98–112. 2019. View Article : Google Scholar : PubMed/NCBI
27	Zhang L, Zhao G, Ji S, Yuan Q and Zhou H: Downregulated long non-coding RNA MSC-AS1 inhibits osteosarcoma progression and increases sensitivity to cisplatin by binding to MicroRNA-142. Med Sci Monit. 26:e9215942020.PubMed/NCBI
28	Kalim M, Iqbal Khan MS and Zhan J: Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy. Chem Biol Drug Des. 95:552–566. 2020. View Article : Google Scholar : PubMed/NCBI
29	Yang M, Hu Z, Yue R, Yang L, Zhang B and Chen Y: The efficacy and safety of qiming granule for dry eye disease: A systematic review and meta-analysis. Front Pharmacol. 11:5802020. View Article : Google Scholar : PubMed/NCBI
30	Zhang J, Chou X, Zhuang M, Zhu C, Hu Y, Cheng D and Liu Z: LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a. J Cell Biochem. 121:4188–4195. 2020. View Article : Google Scholar : PubMed/NCBI
31	Xue C, Xu Y, Ye W, Xie Q, Gao H, Xu B, Zhang D and Jiang J: Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. Gynecol Oncol. 157:222–233. 2020. View Article : Google Scholar : PubMed/NCBI
32	Zuo Y, Zheng W, Liu J, Tang Q, Wang SS and Yang XS: MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Neoplasma. 67:93–101. 2020. View Article : Google Scholar